sur INTEGRAGEN (EPA:ALINT)
IntegraGen Maintains Its Operations Pending the Court of Appeal's Decision
On October 26, 2026, IntegraGen announced it would continue operations despite the ongoing receivership proceedings. Specializing in genomics, the company is awaiting the decision of the Paris Court of Appeal regarding its fate. Two previous rulings had halted its sale to ABL Diagnostics and its liquidation. These decisions are suspended following an appeal by the public prosecutor.
IntegraGen continues to operate, supported by its CLIA/CAP accredited laboratory. The company anticipates maintaining operations until the end of 2026, based on its cash flow projections. However, uncertainty remains for shareholders, who are exposed to potential losses. CEO Bérengère Génin reaffirms the company's commitment to continuing its high-quality services.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INTEGRAGEN